Pfizer (PFE) and Bristol-Meyers (BMY) win FDA approval for Eliquis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
ELIQUIS Receives FDA Approval in Reducing Certain Risks in Nonvalvular Atrial Fibrillation
January 2, 2013 8:03 AM ESTBristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) approved ELIQUIS® (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Atrial fibrillation, the most common type of irregular heartbeat, affects approximately 5.8 million people in the U.S., and results in a five times greater risk of stroke. In the U.S., 15 percent of strokes are attributable to atrial fibrillation.
The approval of ELIQUIS offers patients with nonvalvular atrial fibrillation a... More
Atlantic Equities Upgrades Bristol-Myers Squibb Co. (BMY) to Neutral
December 31, 2012 8:34 AM ESTAtlantic Equities upgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Underweight to Neutral following FDA approval of ELIQUIS.
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more... More
Bristol-Myers (BMY), Pfizer (PFE) Receive Approval for ELIQUIS in Japan
December 26, 2012 7:30 AM ESTBristol-Myers Squibb (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved ELIQUIS (apixaban) for the prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). ELIQUIS is a novel anticoagulant that has demonstrated risk reductions versus warfarin in three important outcomes of stroke, major bleeding and all-cause death. ELIQUIS is an oral direct Factor Xa inhibitor, part of a novel therapeutic class. This is the third approval for ELIQUIS for the prevention of stroke and... More
